In conclusion, fucosylation of HLA-DRB1 is a key regulator of itIC abundance in melanomas, and this mechanism, together with fucosylation-regulated CD4+ T cell biology, can be therapeutically exploited using oral l-fuc administration. Here, CD4 is linked to melanoma.